Normal scar tissue forms to heal an internal wound and quietly retreats when the job is done. But in many common diseases — kidney, liver and lung fibrosis — the scar tissue goes rogue and strangles vital organs. These diseases are largely untreatable and ultimately fatal.
A new Northwestern Medicine study has newly identified a trigger of some fibrotic diseases and an experimental compound to treat it.
Fibrosis — a progressive scarring and hardening of internal organs — is estimated to cause 35 to 40 percent of deaths in the world. Fibrotic diseases include diabetic kidney fibrosis, alcoholic liver cirrhosis, hepatitis C, pulmonary fibrosis and nonalcoholic fatty liver disease, which may lead to fibrosis of the liver, the leading cause of liver transplant.
In one subset of human fibrosis cells, scientists discovered a delinquent gang of molecules that continually shouted at an immune receptor — the antennae on the cell — to produce scar tissue instead of quieting down and allowing the scar tissue to go back to sleep.
Scientists collaborated with a University of Colorado researcher who used crystallography and computer modeling to predict a molecule that could block the receptor that leads to the uncontrolled scarring. When they tested the molecule, T53, in three different mouse models of fibrosis, the abnormality was significantly reversed.
“Our study opens a new door into fibrosis by looking at it as an aberrant innate immune response and suggesting a novel approach to treat it,” said senior author Dr. John Varga, director of the Northwestern Scleroderma Program and the John and Nancy Hughes Distinguished Professor of Rheumatology at Northwestern University Feinberg School of Medicine.
The paper was published July 12 in the Journal of Clinical Investigation Insight.
“The leading cause of liver failure in western world is obesity and that’s because of liver fibrosis,” Varga said. “In the U.S., many of these diseases are lifestyle or age dependent. As we get fatter or older, they get worse.”
Most fibrotic disease likely begins as normal repair of an injury, scientists said. “But if the immune system produces too much of an initial scar, it can’t go back to normal,” Varga said. “You have an unhealed scar that keeps growing and can wipe out the entire organ.”
Not everyone’s fibrosis is caused by the same abnormality, Varga said. If the compound, T53, is eventually developed into an approved drug, it would be targeted to patients with the specific genetic signature identified in the study.
“There is an emerging direction for treating fibrosis with precision medicine,” said first author Swati Bhattacharyya, research associate professor of medicine in rheumatology and scientific director of the Scleroderma Research Laboratory at Feinberg. “Some people live with fibrotic disease for 30 years while others die in two years. We need to identify the rapid progressors from the slow progressors. That’s where precision medicine becomes really critical.”
“The results of this study are encouraging,” Varga said. “We are not saying this compound is ready to be a drug. It’s an initial compound that would need to be developed and tweaked. It would need significant funding to go to the next step.”
Learn more: Why internal scars won’t stop growing
The Latest on: Fibrosis
via Google News
The Latest on: Fibrosis
- 'Full House' cast rallies around Andrea Barber after her mother's deathon January 13, 2021 at 7:10 am
Fuller House” star Andrea Barber announced her mother has died in an emotional Instagram post on Tuesday. “My beautiful mother, Sherry Barber, passed away a few days ago after almost four years of ...
- Support Group for People with Lung Disease at RWJ University Hospital Rahwayon January 13, 2021 at 6:30 am
Robert Wood Johnson University Hospital Rahway is pleased to offer a Lung Disease Support Group for people with COPD, Interstitial Lung Disease, such as Pulmonary Fibrosis or ...
- Kidney/Renal Fibrosis Treatment Market to rise at CAGR of 3.5% by 2027on January 13, 2021 at 6:11 am
The global Kidney/Renal Fibrosis Treatment Market research report, published by Value Market Research, is designed to offer various market framework such as market size, portion, trends, growth path, ...
- 10-year-old-girl who asked for 100 birthday cards receives more than 900on January 12, 2021 at 5:11 pm
A former U.P. resident who just turned 10 asked for 100 cards for her birthday, she ended up with more than 900 ...
- Medicare Coverage for Cystic Fibrosis: Testing, Management, and Treatmentson January 12, 2021 at 1:31 pm
Medicare covers the testing, treatment, and care you need for cystic fibrosis. Find out exactly what's covered by the different parts of Medicare.
- First Patient Enrolls In PRECISIONS Study For Treatment Of Idiopathic Pulmonary Fibrosison January 12, 2021 at 1:49 am
The Pulmonary Fibrosis Foundation announced enrollment of the first patient in the PRECISIONS study. PRECISIONS is the first clinical trial to apply the principles of precision medicine to the ...
- Vertex Pharma taking more aggressive M&A stance, flush with cash from cystic fibrosis drugson January 11, 2021 at 8:40 am
With its balance sheet growing with cash from its cystic fibrosis drugs, Vertex has the “financial firepower” to consider deals, CEO says.
- Benefits of 'transformational' cystic fibrosis drug highlighted in new reviewon January 11, 2021 at 6:22 am
A new systematic review by University of Liverpool researchers highlights the positive impact that triple-combination therapy has on the wellbeing of people with Cystic Fibrosis (CF).
- Dallas respiratory therapist commits to helping patients, even as cystic fibrosis puts her at riskon January 8, 2021 at 8:18 pm
When the coronavirus pandemic began, everyone told Breanna Pierce what she should do. Her doctors suggested and her family urged: Take a break from working as a respiratory therapist. The risks were ...
via Bing News